Madrigal Pharmaceuticals
MDGL
205 hedge funds and large institutions have $2.54B invested in Madrigal Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 89 increasing their positions, 54 reducing their positions, and 38 closing their positions.
102% more call options, than puts
Call options by funds: $225M | Put options by funds: $111M
65% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 54
12.83% more ownership
Funds ownership: 81.18% → 94.02% (+13%)
3% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 38
1% less funds holding
Funds holding: 208 → 205 (-3)
26% less capital invested
Capital invested by funds: $3.43B → $2.54B (-$890M)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$293M |
| 2 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$45.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$38.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$36.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$79.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$33.6M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$19.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$15.7M |
| 5 |
O
OrbiMed
New York
|
-$12.8M |
MDGL Hedge Fund Activity: Q3 2023 in Review
205 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2023, worth a combined $2.54B — down 26% from $3.43B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of MDGL and 37 opened new positions — a net loss of 1 holder — while 54 trimmed existing stakes and 89 added.
The largest buyer was Janus Henderson Group, adding an estimated $293M. The largest seller was Assenagon Asset Management, cutting an estimated $79.9M.
- 205 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2023, down from 208 in Q2 2023.
- Funds reported $2.54B of Madrigal Pharmaceuticals stock for Q3 2023, down 26% quarter-over-quarter.
- 37 funds opened new Madrigal Pharmaceuticals positions in Q3 2023 and 38 closed out, a net change of -1 holder.
- The largest Madrigal Pharmaceuticals buyer in Q3 2023 was Janus Henderson Group, an estimated $293M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2023 was Assenagon Asset Management, an estimated $79.9M sold.
Based on aggregated 13F filings for Q3 2023.